Overview

* Ovid Therapeutics ( OVID ) Q3 revenue slightly beats analyst expectations

* Meg Alexander appointed CEO, effective January 2026

Outlook

* Ovid plans Phase 2a trial for OV329 in Q2 2026

* Company expects OV350 data in Q4 2025

* Ovid anticipates OV4071 clinical trial start in Q2 2026

Result Drivers

* Research and development expenses were $5.9 million for the third quarter ended September 30, 2025, compared to $7.9 million for the same period in 2024

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Slight $132,000 $131,430

Revenue Beat* (7

Analysts

)

Q3 EPS -$0.17

Q3 Net -$12.16

Income mln

Q3 $12.66

Operatin mln

g

Expenses

*Applies to a deviation of less than 1%; not applicable for per-share numbers.

Analyst Coverage

* The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 8 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy."

* Wall Street's median 12-month price target for Ovid Therapeutics Inc ( OVID ) is $4.50, about 70% above its November 11 closing price of $1.35

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)